Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ParkerVision says Federal Circuit remands Qualcomm patent case to Florida district court

ParkerVision says Federal Circuit remands Qualcomm patent case to Florida district court

BitgetBitget2026/10/01 11:00
  • ParkerVision’s patent case against Qualcomm was remanded to the Middle District of Florida after the Federal Circuit dismissed an appeal for lack of jurisdiction.
  • The ruling leaves the receiver-claim construction issue unresolved, with the court saying it did not reach the merits.
  • ParkerVision plans to pursue a jury trial on transmitter patent claims, with a damages request of about $440 million.
  • The company said it will preserve its right to appeal the receiver-claim construction following a final district court ruling in the transmitter case.
  • The Federal Circuit denied ParkerVision’s request to reassign the case to a new district judge.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ParkerVision Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610010700ACCESSWRNAPR_____1229947) on October 01, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Caribou shares plunge as company explores sale and cancels cancer project

October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)

路透社•2026/10/07 09:39